For the quarter ending 2026-03-31, FENC had $8,078K increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net loss | 5,155 | -637 | -4,317 |
| Inventory reserve | - | -517 | - |
| Allowance for credit losses | -120 | -1,155 | 1,222 |
| Amortization of debt discount | - | 12 | 26 |
| Loss on securities | - | 0 | 2 |
| Amortization of contract asset | -51 | 26 | 51 |
| Equity-based compensation | -3,521 | 2,219 | 2,292 |
| Accounts receivable | -13,494 | 3,440 | 5,542 |
| Prepaid expenses | 1,404 | -3,340 | 1,659 |
| Other assets | - | -520 | 435 |
| Inventory | -1,126 | 276 | 1,141 |
| Other current assets | 891 | - | - |
| Other non-current assets | 1,460 | - | - |
| Accounts payable | -979 | -75 | 2,700 |
| Accrued liabilities | -2,851 | 1,476 | -1,203 |
| Net cash (used in)/provided by operating activities | 8,890 | 1,493 | -8,004 |
| Issuance of shares, options exercise | -662 | 1,799 | 186 |
| Cash paid for taxes on restricted share release | 150 | 50 | 111 |
| Net cash provided by/(used in) by financing activities | -812 | 1,749 | 75 |
| Increase in cash and cash equivalents | 8,078 | 3,242 | -7,929 |
| Cash and cash equivalents - beginning of year | 21,947 | 26,634 | - |
| Cash and cash equivalents - end of year | 40,179 | 21,947 | - |
FENNEC PHARMACEUTICALS INC. (FENC)
FENNEC PHARMACEUTICALS INC. (FENC)